Helicos

The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.

The company is currently working with three hospitals in China and plans to launch the GenoCare system commercially in 2017.

This article was originally published Sept. 29.

NEW YORK (GenomeWeb) – Startup SeqLL has closed a $1 million Series A financing round, which it said it will use to enhance Helicos BioSciences' single-molecule sequencing technology for scientific and diagnostic applications. Genomic Diagnostic Technologies led the investment.

Authors of a recent study in BMC Research Notes have concluded that archeological control testing and targeted verification testing are key to avoiding false-positive pathogen identification when

NEW YORK (GenomeWeb News) – Researchers at Brown University and the St. Laurent Institute have found ties between RNA editing and transposon-related gene silencing in fruit flies — findings that they suspect may extend to other organisms.

NEW YORK (GenomeWeb News) – The US bankruptcy court in charge of Helicos BioSciences' Chapter 11 bankruptcy reorganization has approved deals for the company to license its intellectual pr

NEW YORK (GenomeWeb News) – Defunct next-generation sequencing technology firm Helicos BioSciences has asked a bankruptcy court to approve the licensing of intellectual property to Illumina, Life Technologies, and Fluidigm.

NEW YORK (GenomeWeb News) – Helicos BioSciences, currently in Chapter 11 bankruptcy protection, is seeking approval from bankruptcy court to sell its assets to an employee who plans to for

Helicos will be able to use cash collateral, at least on an interim basis, to continue funding its operations as it navigates its way through the bankruptcy process and attempts to sell off its intellectual property, according to an order issued last month from the US Bankruptcy

Pages

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.